You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry

Article info

Article menu

Download PDFPDF

Friday 07 October 2022 from 13:00 to 14:10
Po.6 E- poster session 6: management and recommendations, old and new therapies/biologics
PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry

Authors

  • T Walhelm Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University ~ Linköping ~ Sweden PubMed articlesGoogle scholar articles
  • L Wirestam Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University ~ Linköping ~ Sweden PubMed articlesGoogle scholar articles
  • I Parodis Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital ~ Stockholm ~ Sweden PubMed articlesGoogle scholar articles
  • C Sjöwall Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University ~ Linköping ~ Sweden PubMed articlesGoogle scholar articles

Citation

Walhelm T, Wirestam L, Parodis I, et al
PO.6.128 Factors associated with survival and discontinuation of antimalarial agents in systemic lupus erythematosus: results from a swedish longitudinal registry
Lupus Science & Medicine 2022;9:doi: 10.1136/lupus-2022-elm2022.149

Publication history

  • First published September 27, 2022.
Online issue publication 
October 13, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.